- Home
- Publications
- Publication Search
- Publication Details
Title
Molnupiravir and Its Antiviral Activity Against COVID-19
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-04-04
DOI
10.3389/fimmu.2022.855496
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
- (2022) Laura Vangeel et al. ANTIVIRAL RESEARCH
- SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
- (2022) Pengfei Li et al. CELL RESEARCH
- Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
- (2022) Delphine Planas et al. NATURE
- Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
- (2022) Elisabetta Cameroni et al. NATURE
- Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
- (2022) Sandile Cele et al. NATURE
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
- (2022) Yunlong Cao et al. NATURE
- Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
- (2022) Lihong Liu et al. NATURE
- An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
- (2022) Awadhesh Kumar Singh et al. Diabetes & Metabolic Syndrome-Clinical Research & Reviews
- Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial
- (2021) Patricia R. M. Rocco et al. EUROPEAN RESPIRATORY JOURNAL
- SARS-CoV-2 vaccination in IBD: more pros than cons
- (2021) Ferdinando D’Amico et al. Nature Reviews Gastroenterology & Hepatology
- Mechanism of SARS-CoV-2 polymerase stalling by remdesivir
- (2021) Goran Kokic et al. Nature Communications
- Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2
- (2021) Wendy P. Painter et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19
- (2021) Steven S. Good et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
- (2021) Masoud Solaymani-Dodaran et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19
- (2021) Eduardo López-Medina et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
- (2021) Angela Wahl et al. NATURE
- Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
- (2021) Kris M. White et al. SCIENCE
- Efficacy and tolerability of bevacizumab in patients with severe Covid-19
- (2021) Jiaojiao Pang et al. Nature Communications
- Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2021) François-Xavier Lescure et al. Lancet Respiratory Medicine
- Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia
- (2021) Yasser Sakr et al. INTENSIVE CARE MEDICINE
- Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
- (2021) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- β-D-N 4-hydroxycytidine (NHC) Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
- (2021) Shuntai Zhou et al. JOURNAL OF INFECTIOUS DISEASES
- Vaccine Breakthrough Infections with SARS-CoV-2 Variants
- (2021) Ezgi Hacisuleyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Considerations for the Discovery and Development of 3-Chymotrypsin-Like Cysteine Protease Inhibitors Targeting SARS-CoV-2 Infection
- (2021) Koen Vandyck et al. Current Opinion in Virology
- Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine
- (2021) Grace P. Ahlqvist et al. ACS Omega
- Remodeling of immunological biomarkers in patients with chronic hepatitis C treated with direct-acting antiviral therapy
- (2021) Isabela Gomes Ribeiro et al. ANTIVIRAL RESEARCH
- A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase
- (2021) Jianyuan Zhao et al. ANTIVIRAL RESEARCH
- A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents
- (2021) Thuc Nguyen Dan Do et al. ANTIVIRAL RESEARCH
- Disease-drug and drug-drug interaction in COVID-19: Risk and assessment
- (2021) Devendra Kumar et al. BIOMEDICINE & PHARMACOTHERAPY
- Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
- (2021) Saye H Khoo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Decoding molnupiravir-induced mutagenesis in SARS-CoV-2
- (2021) Luis Menéndez-Arias JOURNAL OF BIOLOGICAL CHEMISTRY
- Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model
- (2021) Rana Abdelnabi et al. JOURNAL OF INFECTIOUS DISEASES
- Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
- (2021) Florian Kabinger et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Artemether, Artesunate, Arteannuin B, Echinatin, Licochalcone B and Andrographolide Effectively Inhibit SARS-CoV-2 and Related Viruses In Vitro
- (2021) Yunjia Hu et al. Frontiers in Cellular and Infection Microbiology
- Comparison of viral RNA–host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2
- (2021) Shaojun Zhang et al. CELL RESEARCH
- Development and validation of assays for the quantification of β-D-N4-hydroxycytidine in human plasma and β-D-N4-hydroxycytidine-triphosphate in peripheral blood mononuclear cell lysates
- (2021) Teresa L. Parsons et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19
- (2021) Mohd. Imran et al. MOLECULES
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
- (2021) Angélica Jayk Bernal et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
- (2021) William A. Fischer et al. Science Translational Medicine
- Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
- (2021) Britton Boras et al. Nature Communications
- Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
- (2021) Robert M. Cox et al. Nature Communications
- Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
- (2021) George R Painter et al. Current Opinion in Virology
- Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
- (2021) Fuxing Lou et al. Frontiers in Immunology
- The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
- (2021) Rana Abdelnabi et al. EBioMedicine
- Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
- (2021) Ching-Chi Lee et al. Antibiotics-Basel
- Molnupiravir in COVID-19: A systematic review of literature
- (2021) Awadhesh Kumar Singh et al. Diabetes & Metabolic Syndrome-Clinical Research & Reviews
- COVID-19: A Review of Potential Treatments (Corticosteroids, Remdesivir, Tocilizumab, Bamlanivimab/Etesevimab, and Casirivimab/Imdevimab) and Pharmacological Considerations
- (2021) Salin Nhean et al. JOURNAL OF PHARMACY PRACTICE
- The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era
- (2021) Huahao Fan et al. Lancet Microbe
- New Flu Antiviral Candidate May Thwart Drug Resistance
- (2020) Tracy Hampton JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Next-generation direct-acting influenza therapeutics
- (2020) Mart Toots et al. Translational Research
- Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model
- (2020) Hua-Hao Fan et al. CHINESE MEDICAL JOURNAL
- Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
- (2020) James M. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
- (2020) Zhen Zhu et al. JOURNAL OF INFECTION
- Clinical Features of Patients with Coronavirus Disease 2019 (COVID‐19) from a Designated Hospital in Beijing, China
- (2020) Lijun Sun et al. JOURNAL OF MEDICAL VIROLOGY
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
- (2020) Ivan Fan-Ngai Hung et al. LANCET
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
- (2020) Yeming Wang et al. LANCET
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
- (2020) Timothy P. Sheahan et al. Science Translational Medicine
- Interferon-α2b Treatment for COVID-19
- (2020) Qiong Zhou et al. Frontiers in Immunology
- Efficacy and safety of interferon β-1a in treatment of severe COVID-19: A randomized clinical trial
- (2020) Effat Davoudi-Monfared et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
- (2020) Chunlong Ma et al. CELL RESEARCH
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
- (2020) Mayla Gabriela Silva Borba et al. JAMA Network Open
- Remdesivir against COVID-19 and Other Viral Diseases
- (2020) Jakob J. Malin et al. CLINICAL MICROBIOLOGY REVIEWS
- Human recombinant soluble ACE2 in severe COVID-19
- (2020) Alexander Zoufaly et al. Lancet Respiratory Medicine
- Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus
- (2020) Shasha Li et al. BRIEFINGS IN BIOINFORMATICS
- Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
- (2020) Eric J. Lenze et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Therapy for Early COVID-19
- (2020) Peter S. Kim et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19
- (2020) Oriol Mitjà et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
- (2020) Carlos Salama et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
- (2020) Ventura A. Simonovich et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global discovery of human-infective RNA viruses: A modelling analysis
- (2020) Feifei Zhang et al. PLoS Pathogens
- Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
- (2020) Robert M. Cox et al. Nature Microbiology
- Nucleoside analogues for the treatment of coronavirus infections
- (2019) Andrea J Pruijssers et al. Current Opinion in Virology
- The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection
- (2019) George R. Painter et al. ANTIVIRAL RESEARCH
- Small-Molecule Antiviral β-D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance
- (2019) Maria L. Agostini et al. JOURNAL OF VIROLOGY
- Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia
- (2019) Mart Toots et al. Science Translational Medicine
- Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model
- (2019) Mart Toots et al. Translational Research
- Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses
- (2018) Jeong-Joong Yoon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A critical appraisal of the sensitivity of in vivo genotoxicity assays in detecting human carcinogens
- (2018) Andreas Zeller et al. MUTAGENESIS
- Epidemiological characteristics of human-infective RNA viruses
- (2018) Mark E. J. Woolhouse et al. Scientific Data
- β-D- N 4 -Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome
- (2017) Nadya Urakova et al. JOURNAL OF VIROLOGY
- Neurological Sequelae Resulting from Encephalitic Alphavirus Infection
- (2016) Shannon E. Ronca et al. Frontiers in Microbiology
- Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication
- (2015) Olivier Reynard et al. Viruses-Basel
- Eastern Equine Encephalitis in Latin America
- (2013) Jean-Paul Carrera et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biochemistry of uridine in plasma
- (2011) Tetsuya Yamamoto et al. CLINICA CHIMICA ACTA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now